BioXcel Therapeutics, Inc. (NASDAQ:BTAI) on Wednesday released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated that BXCL501 had continued ...

(Reuters) -BioXcel Therapeutics Inc said on Monday it will cut more than half of its workforce, as the drugmaker shifts its focus towards developing its agitation treatment for use in at-home settings ...

Findings from a phase 3 trial showed treatment with AVP-786 did not significantly improve agitation associated with dementia due to Alzheimer disease vs placebo. Otsuka Pharmaceuticals has ended the ...

Trial met primary endpoint with the 60 mcg dose, with BXCL501 demonstrating a statistically significant 39% greater reduction in PEC score from baseline compared to placebo at 2 hours (p=0.0112) Met ...

Neumora Therapeutics’ oral Alzheimer’s disease agitation drug has shown benefit, reducing agitation, in a Phase Ib trial. In the study (NCT06546995), the 71 patients from the modified analysis set ...

Neumora Therapeutics, Inc. (NASDAQ: NMRA) on Monday shared results from its Phase 1b signal-seeking study of NMRA-511 for Alzheimer’s disease (AD) agitation. NMRA-511 demonstrated a clinically ...

Music, light, and digital therapies show promise as safer alternatives to risky medications in easing dementia-related agitation, offering a potential path for some patients and caregivers alike.

Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease May 1, 2026 8:00 ...

Agitation is a neuropsychiatric symptom in patients with Alzheimer's disease (AD), the most common form of dementia. The prevalence of this symptom is about 40%-65% ...